Search

Search Constraints

You searched for: Author/Creator Hubner, R

Search Results

2. NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC). Issue 2 (5th February 2020)

3. O-021Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH). (2nd July 2019)

6. P-11730-day mortality associated with systemic anti-cancer therapy (SACT) in gastrointestinal malignancies: The Christie experience. (20th June 2018)